CRDF
Price
$2.06
Change
+$0.02 (+0.98%)
Updated
Sep 26 closing price
Capitalization
137.04M
32 days until earnings call
DYAI
Price
$1.10
Change
-$0.07 (-5.98%)
Updated
Sep 26 closing price
Capitalization
39.81M
38 days until earnings call
Interact to see
Advertisement

CRDF vs DYAI

Header iconCRDF vs DYAI Comparison
Open Charts CRDF vs DYAIBanner chart's image
Cardiff Oncology
Price$2.06
Change+$0.02 (+0.98%)
Volume$594.43K
Capitalization137.04M
Dyadic International
Price$1.10
Change-$0.07 (-5.98%)
Volume$76.46K
Capitalization39.81M
CRDF vs DYAI Comparison Chart in %
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. DYAI commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Buy and DYAI is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (CRDF: $2.06 vs. DYAI: $1.10)
Brand notoriety: CRDF and DYAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 31% vs. DYAI: 42%
Market capitalization -- CRDF: $137.04M vs. DYAI: $39.81M
CRDF [@Biotechnology] is valued at $137.04M. DYAI’s [@Biotechnology] market capitalization is $39.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileDYAI’s FA Score has 0 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • DYAI’s FA Score: 0 green, 5 red.
According to our system of comparison, DYAI is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 6 TA indicator(s) are bullish while DYAI’s TA Score has 6 bullish TA indicator(s).

  • CRDF’s TA Score: 6 bullish, 2 bearish.
  • DYAI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than DYAI.

Price Growth

CRDF (@Biotechnology) experienced а +0.49% price change this week, while DYAI (@Biotechnology) price change was +2.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

CRDF is expected to report earnings on Oct 30, 2025.

DYAI is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDF($137M) has a higher market cap than DYAI($39.8M). DYAI YTD gains are higher at: -37.143 vs. CRDF (-52.535). DYAI has higher annual earnings (EBITDA): -5.09M vs. CRDF (-53.95M). CRDF has more cash in the bank: 71M vs. DYAI (4.98M). CRDF has less debt than DYAI: CRDF (1.19M) vs DYAI (5.06M). DYAI has higher revenues than CRDF: DYAI (3.42M) vs CRDF (545K).
CRDFDYAICRDF / DYAI
Capitalization137M39.8M344%
EBITDA-53.95M-5.09M1,059%
Gain YTD-52.535-37.143141%
P/E RatioN/AN/A-
Revenue545K3.42M16%
Total Cash71M4.98M1,425%
Total Debt1.19M5.06M23%
FUNDAMENTALS RATINGS
CRDF vs DYAI: Fundamental Ratings
CRDF
DYAI
OUTLOOK RATING
1..100
1632
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9050
P/E GROWTH RATING
1..100
10065
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (54) in the null industry is somewhat better than the same rating for DYAI (93) in the Biotechnology industry. This means that CRDF’s stock grew somewhat faster than DYAI’s over the last 12 months.

CRDF's Profit vs Risk Rating (100) in the null industry is in the same range as DYAI (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to DYAI’s over the last 12 months.

CRDF's SMR Rating (99) in the null industry is in the same range as DYAI (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to DYAI’s over the last 12 months.

DYAI's Price Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for CRDF (90) in the null industry. This means that DYAI’s stock grew somewhat faster than CRDF’s over the last 12 months.

DYAI's P/E Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for CRDF (100) in the null industry. This means that DYAI’s stock grew somewhat faster than CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFDYAI
RSI
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 4 days ago
84%
MACD
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
86%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 13 days ago
88%
Bearish Trend 14 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MEPDF15.90N/A
N/A
Medipal Holdings Corp.
IONGF0.03N/A
N/A
Lithium ION Energy Ltd.
INNPD7.47N/A
N/A
Innocan Pharma Corp.
JMHLY61.60-0.29
-0.47%
Jardine Matheson Holdings Ltd.
ORENF4.52-0.13
-2.80%
Origin Enterprises PLC

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with MRVI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then MRVI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
+0.98%
MRVI - CRDF
42%
Loosely correlated
+4.83%
NAMS - CRDF
41%
Loosely correlated
+8.41%
ABSI - CRDF
38%
Loosely correlated
+3.02%
NRIX - CRDF
38%
Loosely correlated
+7.20%
AKBLF - CRDF
37%
Loosely correlated
N/A
More

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and ATON have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and ATON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
-5.98%
ATON - DYAI
29%
Poorly correlated
-7.68%
CRDF - DYAI
28%
Poorly correlated
+0.98%
QSI - DYAI
24%
Poorly correlated
-1.32%
NAUT - DYAI
23%
Poorly correlated
+0.81%
LEGN - DYAI
23%
Poorly correlated
+1.68%
More